NEXT Pharma is proud to announce the launch of Obetinext (Obeticholic Acid), a pioneering therapeutic agent poised to redefine the management of chronic liver diseases, particularly Primary Biliary Cholangitis (PBC), and contribute to broader metabolic health.

NEXT Pharma is committed to ensuring healthcare providers have comprehensive support and information for optimal patient management, including monitoring for liver function and other potential effects.

The launch of Obetinext embodies NEXT Pharma’s dedication to innovation and our relentless pursuit of solutions that significantly improve patient quality of life. This new therapy represents a beacon of hope for individuals facing chronic liver conditions, reinforcing our position at the forefront of pharmaceutical advancements in metabolic and hepatobiliary health.